Liraglutide and Renal Outcomes in Type 2 Diabetes.
| Author | |
|---|---|
| Abstract |
:
In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. |
| Year of Publication |
:
2017
|
| Journal |
:
The New England journal of medicine
|
| Volume |
:
377
|
| Issue |
:
9
|
| Number of Pages |
:
839-848
|
| Date Published |
:
2017
|
| ISSN Number |
:
0028-4793
|
| URL |
:
https://www.nejm.org/doi/10.1056/NEJMoa1616011?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov
|
| DOI |
:
10.1056/NEJMoa1616011
|
| Short Title |
:
N Engl J Med
|
| Download citation |
